Expression of interleukin-8 receptor CXCR2 and suppressor of cytokine signaling-3 in Astrocytic tumors

Molecular Medicine

Volumn 18, Issue 3, 2012, Pages 379-388

  Korkolopoulou, Penelope ^a   Levidou, Georgia ^a   El Habr, Elias A ^a   Adamopoulos, Christos ^a   Samaras, Vassilis ^b   Zisakis, Athanasios ^a   Kavantzas, Nikolaos ^a   Boviatsis, Efstathios ^a   Fragkou, Paraskevi ^a   Papavassiliou, Athanasios G ^a   Patsouris, Efstratios ^a   Piperi, Christina ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b RED CROSS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; INTERLEUKIN 8; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; VASCULOTROPIN;

ADULT; AGED; ARTICLE; ASTROCYTE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL DENSITY; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GLIOBLASTOMA; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NECROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; UNIVARIATE ANALYSIS; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; FEMALE; HUMANS; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-8B; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84860439625     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00449     Document Type: Article

References (41)

1. Maher EA, et al. (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15:1311-1333.
2. Brat DJ, Bellail AC, Van Meir EG. (2005) The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro. Oncol. 7:122-133.
3. Murphy PM, Tiffany HL. (1991) Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science. 253:1280-1283.
4. Raychaudhuri B, Vogelbaum MA. (2011) IL-8 is a mediator of NFκB induced invasion by gliomas. J. Neurooncol. 101:227-235.
5. Richardson RM, Marjoram RJ, Barak LS, Snyder-man R. (2003) Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170:2904-2911.
6. Brantley EC, et al. (2008) Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin. Cancer Res. 14:4694-4704.
7. Piperi C, et al. (2011) Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: correlation with IL-6, VEGF and microvessel morphom-etry. Cytokine. 55:387-395.
8. de la Iglesia N, et al. (2008) Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and inva-siveness. J. Neurosci. 28:5870-5878.
9. Wormald S, Hilton DJ. (2004) Inhibitors of cy-tokine signal transduction. J. Biol. Chem. 279:821-824.
10. Baker BJ, Akhtar LN, Benveniste EN. (2009) SOCS1 and SOCS3 in the control of CNS immunity. Trends Immunol. 30:392-400.
11. Zhou H, et al. (2007) Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. Clin. Cancer Res. 13:2344-2353.
12. Matsuo Y, et al. (2009) CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int. J. Cancer. 125:1027-1037.
13. Li A, et al. (2005) Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and an-giogenesis. Angiogenesis. 8:63-71.
14. Louis DN, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97-109.
15. Samaras V, et al. (2007) Application of the ELISPOT method for comparative analysis of in-terleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumours. Mol. Cell. Biochem. 304:343-51.
16. Zisakis A, et al. (2007) Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine. 39:99-105.
17. Korkolopoulou P, et al. (2002) Prognostic implications of microvessel morphometry in diffuse as-trocytic neoplasms. Neuropathol. Appl. Neurobiol. 28:57-66.
18. Korkolopoulou P, et al. (2007) Expression of hypoxia-related tissue factors in astrocytic gliomas: a multivariate survival study with emphasis upon carbonic anhydrase IX. Hum. Pathol. 38:629-638.
19. Hsieh FY, Lavori PW. (2000) Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin. Trials. 21:552-560.
20. Lachin JM, Foulkes MA. (1986) Evaluation of sample size and power analysis of survival with allowance for nonuniform patient entry, losses to follow-up noncompliance and stratification. Biometrics. 42:507-519.
21. Desbaillets I, Diserens AC, Tribolet N, Hamou MF, Van Meir EG. (1997) Upregulation of inter-leukin 8 by oxygen-deprived cells in glioblas-toma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J. Exp. Med. 186:1201-1212.
22. Zhou Y, Larsen PH, Hao C, Yong VW. (2002) CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J. Biol. Chem. 277:49481-49487.
23. Van Meir E, et al. (1992) Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system. Cancer Res. 52:4297-4205.
24. Gabellini C, et al. (2009) Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur. J. Cancer. 45:2618-2627.
25. Samaras V, et al. (2009) Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel mor-phometry. Human Immunol. 70:391-397.
26. Oladipo O, et al. (2011) The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. Br. J. Cancer. 104:480-487.
27. Liu Z, Yang L, Xu J, Zhang X, Wang B. (2011) Enhanced expression and clinical significance of chemokine receptor CXCR2 in hepatocellular carcinoma. J. Surg. Res. 166:241-246.
28. Cheng WL, et al. (2011) Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann. Oncol. 22:2267-2276.
29. Yamamoto M, et al. (2008) TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer Res. 68:9754-9762.
30. Yang G, et al. (2010) CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogene-sis. Clin. Cancer Res. 16:3875-3886.
31. Wang D, et al. (2000) MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression. Oncogene. 19:4647-4659.
32. Burger M, Hartmann T, Burger JA, Schraufstatter I. (2005) KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene. 24:2067-2075.
33. Waugh DJ, Wilson C. (2008) The interleukin-8 pathway in cancer. Clin. Cancer Res. 14:6735-6741.
34. Singh S, Varney M, Singh RK. (2009) Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res. 69:411-415.
35. Li A, et al. (2011) Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am. J. Pathol. 178:1340-1349.
36. Martini M, et al. (2008) Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int. J. Cancer. 123:2955-2960.
37. Puhr M, et al. (2009) Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Res. 69:7375-7384.
38. Sasi W, Jiang WG, Sharma A, Mokbel K. (2010) Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer. 10:178.
39. Brender C, et al. (2001) STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood. 97:1056.
40. Huang WT, et al. (2009) Expression of signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 in urothelial carcinoma. Kaohsiung J. Med. Sci. 25:640-646.
41. Lu Y, et al. (2006) Loss of SOCS3 gene expression converts STAT3 function from anti-apoptotic to pro-apoptotic. J. Biol. Chem. 281:36683-36690.